Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2006

Study Completion Date

July 31, 2007

Conditions
Pain
Interventions
DRUG

OraVescent Fentanyl

Trial Locations (21)

11599

Five Towns Neuroscience Research, Lawrence

19611

Clinical Research Center, West Reading

23454

Advanced Pain Management, Virginia Beach

27103

Center for Clinical Research, Winston-Salem

27401

PharmQuest, Greensboro

30060

Comprehensive Pain Care, PC, Marietta

30066

Drug Studies America, Marietta

32216

Jacksonville Center for Clinical Research, Jacksonville

32806

Atlas Research, Orlando

33324

Gold Coast Research, LLC, Plantation

33334

Centre for Rheumatology, Fort Lauderdale

59802

Montana Neuroscience Institute, Missoula

64055

Pain Management Associates, Independence

70065

Best Clinical Trials, Inc., New Orleans

70115

Best Clinical Trials, LLC, New Orleans

71913

Hot Springs Pain Clinic, Hot Springs

87108

Lovelace Scientific Resources, Albuquerque

92032

Samaritan Center for Medical, Los Gatos

93030

Pacific Neuroscience Medical Group, Inc., Oxnard

97227

Legacy Emanuel Pain Management, PC, Portland

02115

Brigham Women's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00343733 - Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain | Biotech Hunter | Biotech Hunter